Eton Pharmaceuticals, Inc. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA on July 29, 2026, seeking to expand KHINDIVI (hydrocortisone oral solution) label approval to pediatric patients under age 5 with adrenocortical insufficiency. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, with potential FDA approval targeted for H1 2027. The expansion targets an estimated 10,000-patient pediatric adrenal insufficiency market in the U.S., aiming to significantly increase KHINDIVI adoption.
Why this rating
Label expansion targeting younger children in rare disease market is meaningful for growth trajectory; real but regulatory approval uncertain and timeline extends to H1 2027.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.